In FA‐ or UUO‐induced CKD models, BLI targets JAK1 and inhibits its phosphorylation and activation of the JAK‐STAT signaling pathway, thereby inhibiting multiple downstream events that promote kidney fibrosis. Here, SOAT1 is linked to chronic kidney disease.